{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Elam RE"],"funding":["NIA NIH HHS"],"pagination":["20"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12783237"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["21(1)"],"pubmed_abstract":["In the U.S's largest integrated health system, during a 24-year period (1999-2022), bisphosphonate treatment initiation for fracture prevention in men shifted towards higher-risk populations, including older men and those with prior fracture and frailty.Purpose
To evaluate 24-year trends in bisphosphonate (BP) initiation among older U.S. male Veterans and shifts in demographic and clinical characteristics of BP-treated men over time.Methods
U.S. national Veterans Health Administration (VHA) data (1999-2022) were queried to identify men aged ≥ 50 years with a first prescription for an FDA-approved BP for fracture prevention. Age, race, ethnicity, BP drug and route, prior fracture, and, in those aged ≥ 65 years, Veterans Affairs Frailty Index (VA-FI), were examined across fiv"],"journal":["Archives of osteoporosis"],"pubmed_title":["Shifting bisphosphonate prescribing patterns for fracture prevention: a 24-year national surveillance of men in the U.S. Veterans Health Administration."],"pmcid":["PMC12783237"],"funding_grant_id":["R01 AG079118","R01AG079118"],"pubmed_authors":["Schousboe JT","Huo Z","Elam RE","Adler RA","Weaver FM","Barzilay J","Budde E","Carbone LD","Lo JC","Fink HA","Jacob R","Ott SM"],"additional_accession":[]},"is_claimable":false,"name":"Shifting bisphosphonate prescribing patterns for fracture prevention: a 24-year national surveillance of men in the U.S. Veterans Health Administration.","description":"In the U.S's largest integrated health system, during a 24-year period (1999-2022), bisphosphonate treatment initiation for fracture prevention in men shifted towards higher-risk populations, including older men and those with prior fracture and frailty.Purpose
To evaluate 24-year trends in bisphosphonate (BP) initiation among older U.S. male Veterans and shifts in demographic and clinical characteristics of BP-treated men over time.Methods
U.S. national Veterans Health Administration (VHA) data (1999-2022) were queried to identify men aged ≥ 50 years with a first prescription for an FDA-approved BP for fracture prevention. Age, race, ethnicity, BP drug and route, prior fracture, and, in those aged ≥ 65 years, Veterans Affairs Frailty Index (VA-FI), were examined across fiv","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-06T11:44:40.49Z","creation":"2026-05-30T03:07:19.412Z"},"accession":"S-EPMC12783237","cross_references":{"pubmed":["41504976"],"doi":["10.1007/s11657-025-01635-z"]}}